FDA review is critical of Amylyx data; a federal failure to address harms of climate crisis

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: FDA review is critical of data on Amylyx ALS drug, but cites 'regulatory flexibility' By Adam Feuerstein Sarah Silbiger/Getty Images Patients with ALS, their caregivers, and advocacy groups have been applying enormous pressure on the FDA to approve AMX0035. Read More STAT+: She was told 'girls don't do that.' Now Margaret-Mary Wilson is a top executive at UnitedHealth Group By Usha Lee McFarling Courtesy Mary-Margaret Wilson Margaret-Mary Wilson was discouraged from her dreams of becoming a doctor because "girls don’t do that." But she persisted. Read More Opinion: HHS's failure to address the health harms of the climate crisis constitutes environmental and institutional racism By David Introcaso PATRICK T. FALLON/AFP via Getty Images Failure to address the health harms of the climate crisis by the Office for Civil Rights constitutes environmental and institutional racism. Read More Sponsor content by STAT Events Last Chance: The STAT Breakthrough Science Summit This Thursday, leaders from Pfizer, Bristol Myers Squibb, and Merck will take the stage to discuss what’s next for their organizations. We’ll also explore the future of CRISPR and unpack the feasibility of pig-to-human transplants. There’s so much more, so check out statnews.com/summit to see the full agenda and find more information about our featured speakers. Then, get your ticket to join us! Monday, March 28, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser